Major depressive disorder (MDD) is the leading cause of disability worldwide. Treatment
with antidepressant drugs (ATD), which target monoamine neurotransmitters including …

Objective Monoamine oxidase-A (MAO-A) is a key mitochondrial enzyme that metabolizes
biogenic amine neurotransmitters such as dopamine and serotonin. Individuals with atypical …

Monoamine oxidase A (MAOA), a mitochondrial enzyme involved in the degradation of
biogenic amines, may be implicated in the pathogenesis of major depressive disorder …

Background Polymorphisms in the monoamine oxidase A (MAOA) gene may influence
treatment outcomes in major depression disorder (MDD). Objective To investigate the …

Genetic differences among patients suffering from Major Depression are likely to contribute
to interindividual differences in medication treatment response. Thus, the identification of …

The monoamine oxidase A (MAO-A) has been suggested to be involved in the pathogenesis
as well as the pharmacological treatment of Major Depression. In the present study, 340 …

This study investigated the possible association of the MAOA T941G gene variant with
differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with …

Menopause is an important event in a woman's life associated with hormonal changes that
play a substantial role in the functioning of her body. A decline in the level of estrogens …

Objective. The aim of the study was an evaluation of possible relationships between
polymorphisms of serotoninergic system genes and the risk of depression in …

It has been proposed that an MAOA abnormality may be an important factor in the
development of major depressive disorder (MDD). Various polymorphisms of the MAOA …